Peer-Reviewed Publication
Crit Care2026;30(1):60.January 27, 2026Journal Article
Endothelial glycocalyx degradation and its association with clinical outcomes and host response aberrations in community-acquired pneumonia across different care settings.
Hui Wang1, Erik H A Michels2, Mingyang Cai3, Joe M Butler2, Justin de Brabander2, Tom D Y Reijnders2, Sebastiaan C Joosten2, Timothy E Sweeney4, Alex R Schuurman2, Tjitske S R van Engelen2, Bastiaan W Haak2, Xanthe Brands2, Renée A Douma5, Olaf C Cremer6, Hessel Peters-Sengers2,3, W Joost Wiersinga2,7, Tom van der Poll2,7
1Center for Infection and Molecular Medicine (CIMM), Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. hui.nerissa.wang@amsterdamumc.nl.
2Center for Infection and Molecular Medicine (CIMM), Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
3Data Science and Epidemiology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
4Inflammatix Inc, Sunnyvale, CA, USA.
5Department of Internal Medicine, Flevo Hospital, Almere, The Netherlands.
6Department of Intensive Care, UMC Utrecht, Utrecht, The Netherlands.
7Division of Infectious Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Abstract
BACKGROUND: Endothelial glycocalyx degradation has been implicated in the pathogenesis of sepsis. Previous studies linked elevated plasma syndecan-1, an established biomarker of glycocalyx disruption, to mortality in sepsis. We aimed to determine the association of plasma syndecan-1 levels with clinical outcomes and host response changes in patients with community-acquired pneumonia (CAP) with var…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans